Abstract: Mast infrastructure element and support module. Disclosed is an infrastructure element (1) comprising: —a mast (2) capable of receiving at least one telecommunication antenna (20), —and at least one support module (3) which is closed at the top and capable of receiving electrical equipment (E) within it permanently, the mast (2) being fastened onto the support module (3) without passing through it vertically, and—at least one non-supporting accessory module (4,5) capable of receiving electrical equipment (E), the accessory module (4,5) being joined laterally to the support module (3).

Abstract: A modular mast (1) intended to be fixed to a bearing element and to accommodate at least one telecommunication antenna includes at least two sections (2 and 3 or 3 and 4) assembled in the extension of one another by respective ends, and one of the sections (2, 3 or 4) having, at its end assembled with the other section (2, 3 or 4), at least one cutout (10) and the latter section having at least one tooth (11) coming axially to bear in the bottom (17) of the cutout (10). At least one seal (15) is present between an edge of the cutout (10) and an adjacent edge of the tooth (11). A plurality of securing plates (12) link the ends of the sections (2 and 3 or 3 and 4) internally therein.

Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Abstract: The present disclosure relates to methods of treating or preventing various diseases or disorders, such as cardiac fibrosis, aortic fibrosis, pulmonary fibrosis, renal fibrosis, dermal fibrosis, and chronic kidney diseases, using cannabidiol derivatives or compositions thereof.

Abstract: A modular foundation including plurality of prefabricated concrete modules defining an upper layer of modules including at least one internal passage opening onto at least its upper and lower faces, at least one lower layer of modules on which the upper layer at least partially rests, including at least one internal passage opening onto at least one of its sides and onto at least its upper face, this internal passage communicating at the level of the interface between the upper layer and the lower layer(s) with the internal passage of the upper layer in such a manner as to form at least one global internal passage in the foundation opening onto at least one side and onto at least the upper face of the foundation.

Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Abstract: Compositions, comprising the cannabidiol derivatives of Formula (I) in pharmaceutical formulations displaying increased bioavailability and solubility are described. Cannabidiol derivatives of Formula (I) and compositions comprising the same for use in the treatment of various conditions, and diseases, including diseases associated with demyelination.

Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Abstract: Provided herein are combinations that include a histone deacetylase inhibitor and tubulin inhibitor such as eribulin or a pharmaceutically acceptable salt thereof that are useful for treating cancer, including reducing cancer metastasis.

Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Abstract: Wide area transport networks for mobile Radio Access Networks, and methods of use are provided herein. An exemplary wide area transport network may include a plurality of network segments that include at least one wireline network and at least one wireless network communicatively coupled with one another. Each of the plurality of network segments may be configured to transmit at least one of a plurality of signals communicated between a baseband module and a wireless transceiver.

Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.

Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.

Abstract: Systems and methods for efficiently transmitting information over a wireless network segment are provided herein. An exemplary method may include separating, via a transmitter, digital fronthaul data into general information and radio signal information, transmitting the general information over the wireless network segment from the transmitter to a receiver on a first communications channel, and transmitting the radio signal information over the wireless network segment from the transmitter to the receiver on a second communications channel.

Abstract: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.